CN108065399A - 一种含硒保健组合物及其应用 - Google Patents
一种含硒保健组合物及其应用 Download PDFInfo
- Publication number
- CN108065399A CN108065399A CN201711499162.4A CN201711499162A CN108065399A CN 108065399 A CN108065399 A CN 108065399A CN 201711499162 A CN201711499162 A CN 201711499162A CN 108065399 A CN108065399 A CN 108065399A
- Authority
- CN
- China
- Prior art keywords
- parts
- health
- health composition
- composition containing
- selenium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000011669 selenium Substances 0.000 title claims abstract description 73
- 230000036541 health Effects 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 58
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 15
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229920002101 Chitin Polymers 0.000 claims abstract description 14
- 229940072056 alginate Drugs 0.000 claims abstract description 14
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 14
- 229920000615 alginic acid Polymers 0.000 claims abstract description 14
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 12
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 12
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 12
- 230000036039 immunity Effects 0.000 claims abstract description 12
- 230000003647 oxidation Effects 0.000 claims abstract description 5
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 5
- 230000001737 promoting effect Effects 0.000 claims abstract description 5
- 230000001772 anti-angiogenic effect Effects 0.000 claims abstract description 4
- 239000002775 capsule Substances 0.000 claims description 8
- 235000015895 biscuits Nutrition 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 235000010410 calcium alginate Nutrition 0.000 claims description 2
- 239000000648 calcium alginate Substances 0.000 claims description 2
- 229960002681 calcium alginate Drugs 0.000 claims description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 230000001055 chewing effect Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 235000013305 food Nutrition 0.000 abstract description 10
- 235000013402 health food Nutrition 0.000 abstract description 7
- 230000007812 deficiency Effects 0.000 abstract description 2
- 235000011649 selenium Nutrition 0.000 description 41
- 229940091258 selenium supplement Drugs 0.000 description 41
- 230000000052 comparative effect Effects 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 230000000242 pagocytic effect Effects 0.000 description 7
- 206010061598 Immunodeficiency Diseases 0.000 description 6
- 208000029462 Immunodeficiency disease Diseases 0.000 description 6
- 230000007813 immunodeficiency Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- -1 lipid peroxide Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000014106 fortified food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000202903 Bergenia purpurascens Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000371652 Curvularia clavata Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XYUNNDAEUQFHGV-UHFFFAOYSA-N [Se].[Se] Chemical compound [Se].[Se] XYUNNDAEUQFHGV-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000783 metal toxicity Toxicity 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种含硒保健组合物及其应用,属于保健食品领域。为了克服目前富硒保健品的保健效果较差,功能疗效不明的技术不足,本发明提供一种含硒保健组合物及其应用,其主要由如下重量份的组分制备得到:甲壳素及其衍生物5份~10份、富硒酵母10份~50份、透明质酸5份~10份、海藻酸盐5份~10份,所述组合物中各组分对于提升免疫力和抗血管氧化具有显著的协同效果,保健作用突出,适合推广应用。
Description
技术领域
本发明涉及一种含硒保健组合物及其应用,属于保健食品领域。
背景技术
富硒食品,就是富含微量元素硒的食品。一般分为天然富硒食品(又称植物活性硒食品),外源硒富硒食品(也称人工有机硒食品),比如黑山药、黑芝麻,黑豆,黑花生,黑米、大蒜、加拿大猪肉等都含有硒元素。硒是人体必需的微量元素。硒参与合成人体内多种含硒酶和含硒蛋白。其中谷胱甘肽过氧化物酶,在生物体内催化氢过氧化物或脂质过氧化物转变为水或各种醇类,消除自由基对生物膜的攻击,保护生物膜免受氧化损伤;硒参与构成碘化甲状腺胺酸脱碘酶。硒能提高人体免疫,促进淋巴细胞的增殖及抗体和免疫球蛋白的合成。硒对结肠癌、皮肤癌、肝癌、乳腺癌等多种癌症具有明显的抑制和防护的作用,其在机体内的中间代谢产物甲基烯醇具有较强的抗癌活性。硒与维生素E、大蒜素、亚油酸、锗、锌等营养素具有协同抗氧化的功效,增加抗氧化活性。同时,硒具有减轻和缓解重金属毒性的作用。
科学界研究发现,血硒水平的高低与癌的发生息息相关。大量的调查资料说明,一个地区食物和土壤中硒含量的高低与癌症的发病率有直接关系,例如:此地区的食物和土壤中的硒含量高,癌症的发病率和死亡率就低,反之,这个地区的癌症发病率和死亡率就高,事实说明硒与癌症的发生有着密切关系。同时科学界也认识到硒具有预防癌症作用,是人体微量元素的“防癌之王”。美国亚利圣那大学癌症中心Clark教授对1312例癌症患者进行13年对照试验。结果表明每日补硒200μg,癌症死亡率下降50%,癌症总发病率下降37%,其中肺癌下降46%,肠癌下降58%,***癌下降63%。2003年美国食品药品管理局(FDA)明示:“硒能降低患癌风险”和“硒可在人体内产生抗癌变作用”。
中国专利申请201610153999.2公开了一种富硒保健品,它所含的活性成分由下列重量份原料配比制备而成:***钠2份、金钮扣50份、黄毛岩白菜60份、紫苏梗80份、百蕊草55份,还公开了其具有益气补血作用。
发明内容
为了克服目前富硒保健品的保健效果较差,功能疗效不明的技术不足,本发明提供一种含硒保健组合物及其应用,其主要由如下重量份的组分制备得到:甲壳素及其衍生物5份~10份、富硒酵母10份~50份、透明质酸5份~10份、海藻酸盐5份~10份,所述组合物中各组分对于提升免疫力和抗血管氧化具有显著的协同效果,保健作用突出,适合推广应用。
本发明通过下述技术方案实现上述技术效果:
一种含硒保健组合物,其主要由如下重量份的组分制备得到:甲壳素及其衍生物5份~10份、富硒酵母10份~50份、透明质酸5份~10份、海藻酸盐5份~10份。
如上所述的含硒保健组合物,所述的甲壳素及其衍生物为壳聚糖、羧甲基壳聚糖、壳聚糖季铵盐、壳寡糖中的一种或多种。
如上所述的含硒保健组合物,所述的海藻酸盐为海藻酸钠、海藻酸钙中的一种或两种。
所述的富硒酵母可采用常规工艺制备得到或者市售得到,但为了保证本发明保健组合物的保健效果,所述的富硒酵母中硒含量不低于350μg/g,有机硒的比率不低于90%。
优选地,含硒保健组合物由如下重量份的组分制备得到:甲壳素及其衍生物7.5份、富硒酵母30份、透明质酸7.5份、海藻酸盐7.5份。
如上所述的含硒保健组合物,所述的组合物可以制备成片剂、胶囊、颗粒、饼干或粉剂。其中所述的片剂优选为包衣片或咀嚼片。
本发明所述的保健组合物具有提高免疫力,排毒护肝,抗氧化、调节三高的作用。实施例6结果显示模型小鼠的廓清指数K和吞噬指数有明显下降,表明免疫低下模型造模成功。而本发明保健组合物各剂量组均可非常明显地增强非特异性免疫功能,主要表现为可以升高免疫低下小鼠的廓清指数K和吞噬指数a。其中保健组合物组的廓清指数K和吞噬指数a与对比实施例1-5组相比具有显著性差异,这表明保健组合物对免疫低下模型的特异性免疫提高优于市售的富硒保健品,且保健组合物中各组分在提高免疫力方面具有显著的协同作用。基于此,本发明请求保护上述保健组合物在制备提升免疫力保健品中的应用。
本发明实施例7表明,模型组大鼠血浆中SOD活力明显降低,MDA含量明显升高,与空白组相比差异均有显著性(P<0.05)。本发明保健组合物均能够提高模型大鼠血浆SOD活力,降低MDA含量,与模型组相比,差异亦有显著性(P<0.05),可见本发明保健组合物组与模型组具有显著性差异。基于此,本发明上述保健组合物在制备抗血管氧化保健品中的应用。
本发明所述的保健组合物与现有技术相比技术优势在于:
1)本发明所述的保健组合物的各种组分具有多种保健用途,其在提高免疫力,排毒护肝,抗氧化、调节三高方面均具有很好的保健价值。
2)本发明通过实验证实,保健组合物对免疫低下模型的特异性免疫提高优于市售的富硒保健品,且保健组合物中各组分在提高免疫力方面具有显著的协同作用。同时本发明实施例7表明,本发明保健组合物均能够提高模型大鼠血浆SOD活力,降低MDA含量,与模型组相比,差异亦有显著性(P<0.05)。
3)本发明所述的保健组合物成分确切,组分之间具有显著协同保健价值,且制备方法简单,适合进行推广应用。
具体实施方式
以下通过具体实施例进一步描述本发明,但所述实施例并不以任何方式限定本发明专利保护范围。
实施例1
一种含硒保健组合物,其主要由如下重量份的组分制备得到:甲壳素及其衍生物5份~10份、富硒酵母10份~50份、透明质酸5份~10份、海藻酸盐5份~10份。
按照常规工艺将上述保健组合物制备成片剂、胶囊、颗粒、饼干或粉剂。
实施例2
一种含硒保健组合物,其主要由如下重量份的组分制备得到:甲壳素及其衍生物5份~10份、富硒酵母10份~50份、透明质酸5份~10份、海藻酸盐5份~10份。
按照常规工艺将上述保健组合物制备成片剂、胶囊、颗粒、饼干或粉剂。
实施例3
一种含硒保健组合物,其主要由如下重量份的组分制备得到:甲壳素及其衍生物5份~10份、富硒酵母10份~50份、透明质酸5份~10份、海藻酸盐5份~10份。
按照常规工艺将上述保健组合物制备成片剂、胶囊、颗粒、饼干或粉剂。
实施例4
一种含硒保健组合物,其主要由如下重量份的组分制备得到:甲壳素及其衍生物5份~10份、富硒酵母10份~50份、透明质酸5份~10份、海藻酸盐5份~10份。
按照常规工艺将上述保健组合物制备成片剂、胶囊、颗粒、饼干或粉剂。
实施例5
一种含硒保健组合物,其主要由如下重量份的组分制备得到:甲壳素及其衍生物5份~10份、富硒酵母10份~50份、透明质酸5份~10份、海藻酸盐5份~10份。
按照常规工艺将上述保健组合物制备成片剂、胶囊、颗粒、饼干或粉剂。
对比实施例1
处方和制备工艺同实施例3,区别在于处方中不含甲壳素及其衍生物。
对比实施例2
处方和制备工艺同实施例3,区别在于处方中不含富硒酵母。
对比实施例3
处方和制备工艺同实施例3,区别在于处方中不含透明质酸。
对比实施例4
处方和制备工艺同实施例3,区别在于处方中不含海藻酸盐。
对比实施例5
按照201610153999.2实施例1制备得到的富硒保健品。
实施例6本发明保健组合物对免疫低下小鼠模型的非特异性免疫功能的影响
1、动物造模及给药
选取体重范围在18-22g之间的ICR小鼠120只,小鼠随机分成12组:正常对照组、模型组、本发明实施例1-5组(给药量3g/kg)、对比实施例1-3组(给药量3g/kg)、,每组10只。除前两组外,每组每日分别灌胃给药喂服保健组合物溶液1次,连续给药7天。除正常组外其他各治疗组动物均于第4天皮下注射环磷酰胺40mg/kg制造免疫低下模型;于给药后第8天经尾静脉注射印度墨汁0.05ml/10g,于1min和5min后分别经眼眶静脉取血20ml,加入0.1%Na2CO3中摇匀,于680rim下比色读取吸光度。按下式计算廓清指数K和吞噬指数a:
K=(lgOD1-lgOD2)/(t2-t1),a=K1/3×体重/肝脾重
统计学方法数据以均数±标准差(±s)表示。组间比较采用组间t检验。以P<0.05为差异有显著性,P<0.01为差异有非常显著性。
2、实验结果及分析
表1各组及不同剂量下廓清指数(K)与吞噬指数(a)比较(x±s,n=10)
组别 | K | a |
正常对照组 | 0.0637±0.0227 | 7.41±0.64 |
模型组 | 0.0354±0.0183** | 7.12±0.58** |
实施例1 | 0.0672±0.0146## | 7.48±0.74## |
实施例2 | 0.0746±0.0108## | 7.65±0.62## |
实施例3 | 0.0788±0.0062## | 7.95±0.71## |
实施例4 | 0.0739±0.0135## | 7.41±0.51## |
实施例5 | 0.0685±0.0162** | 7.62±0.58** |
对比实施例1 | 0.0443±0.0124# | 7.23±0.44 |
对比实施例2 | 0.0376±0.0134## | 7.35±0.38# |
对比实施例3 | 0.0388±0.1321 | 7.17±0.16 |
对比实施例4 | 0.0417±0.0127# | 7.20±0.25 |
对比实施例5 | 0.0513±0.0061# | 7.16±0.41 |
与正常组相比,**P<0.01;与模型组相比,##P<0.01;
由表1结果显示模型小鼠的廓清指数K和吞噬指数有明显下降,表明免疫低下模型造模成功。而本发明保健组合物各剂量组均可非常明显地增强非特异性免疫功能,主要表现为可以升高免疫低下小鼠的廓清指数K和吞噬指数a。其中保健组合物组的廓清指数K和吞噬指数a与对比实施例1-5组相比具有显著性差异,这表明保健组合物对免疫低下模型的特异性免疫提高优于市售的富硒保健品,且保健组合物中各组分在提高免疫力方面具有显著的协同作用。
实施例7本发明保健组合物对动脉粥样硬化大鼠过氧化物***的影响
动物:清洁级wistar大鼠,60只,雄性,体重220-240g,由上海斯莱克实验动物有限责任公司提供。其中,空白对照组大鼠喂以SPF级实验鼠颗粒饲料、普通饮水饲养;
大鼠动脉粥样硬化模型(AS):以配方为3%胆固醇、0.5%胆酸钠、0.12%丙基硫氧嘧啶、5%白糖、10%猪油、81.38%基础饲料的高脂饲料喂养大鼠,同时灌胃予以维生素D315万U/kg,造模期给予VD3周期为每周一次,分组给药后延长为每十天一次,以此建立大鼠AS模型。造模开始6周后随机抽取3只模型大鼠检验造模情况,检测发现血脂异常(TG、TC增高),主动脉内膜增厚、弹性下降、肉眼可见脂质斑块,提示造模成功。造模成功后,分别给予下述药物给药,各组灌胃给药,每日一次,给药容积为10ml/kg。共8周。各组分别给予下述治疗药物:
模型对照组:灌胃给予同体积生理盐水;
实施例1组:灌胃给予实施例1制备的生药量为3g/kg·d的保健组合物片剂;
实施例2组:灌胃给予实施例2制备的生药量为3g/kg·d的保健组合物片剂;
实施例3组:灌胃给予实施例3制备的生药量为3g/kg·d的保健组合物粉剂;
实施例4组:灌胃给予实施例4制备的生药量为3g/kg·d的保健组合物片剂;
实施例5组:灌胃给予实施例5制备的生药量为3g/kg·d保健组合物胶囊剂
检测:大鼠颈总动脉取血,加入抗凝管中(3.8%枸橼酸钠1∶9抗凝),静置后离心(3000rpm,10min)分离血浆。采用硝酸还原酶法检测血浆中SOD含量,ASkawa法检测血浆中MDA含量。
3实验结果:
表2结果表明,模型组大鼠血浆中SOD活力明显降低,MDA含量明显升高,与空白组相比差异均有显著性(P<0.05)。本发明保健组合物均能够提高模型大鼠血浆SOD活力,降低MDA含量,与模型组相比,差异亦有显著性(P<0.05),可见本发明保健组合物组与阳性对照组具有显著性差异。
表2本发明保健组合物对动脉粥样硬化大鼠过氧化物***的影响
●与模型组比较p<0.05,●●与模型组比较p<0.01。
Claims (9)
1.一种含硒保健组合物,其主要由如下重量份的组分制备得到:甲壳素及其衍生物5份~10份、富硒酵母10份~50份、透明质酸5份~10份、海藻酸盐5份~10份。
2.根据权利要求1所述的含硒保健组合物,其特征在于,所述的甲壳素及其衍生物为壳聚糖、羧甲基壳聚糖、壳聚糖季铵盐、壳寡糖中的一种或多种。
3.根据权利要求1所述的含硒保健组合物,其特征在于,所述的海藻酸盐为海藻酸钠、海藻酸钙中的一种或两种。
4.根据权利要求1所述的含硒保健组合物,其特征在于,所述的富硒酵母中硒含量不低于350μg/g,有机硒的比率不低于90%。
5.根据权利要求1所述的含硒保健组合物,其特征在于,含硒保健组合物由如下重量份的组分制备得到:甲壳素及其衍生物7.5份、富硒酵母30份、透明质酸7.5份、海藻酸盐7.5份。
6.根据权利要求1所述的含硒保健组合物,其特征在于,所述的保健组合物为其片剂、胶囊、颗粒、饼干或粉剂。
7.根据权利要求6所述的含硒保健组合物,其特征在于,所述的片剂为包衣片或咀嚼片。
8.权利要求1-7所述的含硒保健组合物在制备提升免疫力保健品中的应用。
9.权利要求1-7所述的含硒保健组合物制备抗血管氧化保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711499162.4A CN108065399A (zh) | 2017-12-29 | 2017-12-29 | 一种含硒保健组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711499162.4A CN108065399A (zh) | 2017-12-29 | 2017-12-29 | 一种含硒保健组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108065399A true CN108065399A (zh) | 2018-05-25 |
Family
ID=62156219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711499162.4A Withdrawn CN108065399A (zh) | 2017-12-29 | 2017-12-29 | 一种含硒保健组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108065399A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106820151A (zh) * | 2016-12-22 | 2017-06-13 | 北京康比特体育科技股份有限公司 | 一种双壳复合保健组合物、制备方法及应用 |
CN111280437A (zh) * | 2018-12-06 | 2020-06-16 | 黄许仙 | 一种含硒保健品及其应用 |
-
2017
- 2017-12-29 CN CN201711499162.4A patent/CN108065399A/zh not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106820151A (zh) * | 2016-12-22 | 2017-06-13 | 北京康比特体育科技股份有限公司 | 一种双壳复合保健组合物、制备方法及应用 |
CN111280437A (zh) * | 2018-12-06 | 2020-06-16 | 黄许仙 | 一种含硒保健品及其应用 |
Non-Patent Citations (2)
Title |
---|
张经纬等: "富硒酵母对高脂饮食大鼠血脂和抗氧化指标的影响 ", 《中国慢性病预防与控制》 * |
秦顺义等: "富硒益生菌对小鼠免疫功能及抗氧化能力的影响 ", 《营养学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Anusiya et al. | A review of the therapeutic and biological effects of edible and wild mushrooms | |
CN107114783A (zh) | 一种增强免疫及辅助肿瘤恢复的高硒营养补充剂 | |
CN102008516B (zh) | 一种***的超微粉中药 | |
CN102715614A (zh) | 一种含有黑大蒜的新饮料 | |
Golak-Siwulska et al. | Nutritional value and health-promoting properties of (Lange) Imbach | |
CN101856384B (zh) | 一种护肝组合物 | |
CN105595337A (zh) | 一种辅助降血糖海藻胶软胶囊及其制备方法 | |
CN104872656A (zh) | 一种具有保健功能的组合物及其制备方法 | |
CN106617049A (zh) | 一种含辣木叶提取物的蜂胶类保健品及其制备方法 | |
Stengler | Health benefits of medicinal mushrooms | |
KR101033671B1 (ko) | 상황버섯과 동충하초를 포함하는 항암용 건강식품 | |
CN108065399A (zh) | 一种含硒保健组合物及其应用 | |
CN104056054B (zh) | 一种抗氧化和增强免疫力的口服制剂及其制备 | |
Elkhateeb et al. | Mushrooms and lichens the factory of important secondary metabolites | |
CN111280437A (zh) | 一种含硒保健品及其应用 | |
KR101568823B1 (ko) | 게르마늄이 함유된 동충하초 추출물을 함유하는 조성물 | |
CN106072569A (zh) | 一种放化疗期间调节病人免疫细胞平衡的特膳食品 | |
CN102846672B (zh) | 一种金针菇益智口服液的制备方法 | |
CN101380102A (zh) | 富硒松花粉健康食品及其制备方法 | |
Rahman | Usage of mushrooms in culinary and medicinal purposes | |
CN108576792A (zh) | 一种复方壳寡糖调理癌症的膳食及其制备方法 | |
CN107927763A (zh) | 一种抗衰老的海洋低温sod保健品 | |
Ghosh et al. | Edible mushroom: a newish arm in medical and agricultural field | |
Sahu et al. | Nutritional and Pharmacological Potential of Edible Mushroom | |
Rahman et al. | Usage of Mushrooms in Culinary and Medicinal Purposes J Nov Psy 2 (1): 14-20 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180525 |
|
WW01 | Invention patent application withdrawn after publication |